These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6428806)

  • 1. Pituitary and ovarian function and clinical performance during the use of a levonorgestrel-releasing intracervical contraceptive device.
    Kurunmäki H; Toivonen J; Lähteenmäki PL; Luukkainen T
    Contraception; 1984 Jan; 29(1):31-43. PubMed ID: 6428806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD.
    Nilsson CG; Lähteenmäki P; Luukkainen T
    Contraception; 1980 Mar; 21(3):225-33. PubMed ID: 6771090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate postabortal contraception with Norplant: levonorgestrel, gonadotropin, estradiol, and progesterone levels over two postabortal months and return of fertility after removal of Norplant capsules.
    Kurunmäki H; Toivonen J; Lähteenmäki PL; Luukkainen T
    Contraception; 1984 Nov; 30(5):431-42. PubMed ID: 6440739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracervical release of levonorgestrel for contraception.
    Kurunmäki H; Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1981 May; 23(5):473-85. PubMed ID: 6793299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further studies on pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1981 Aug; 24(2):159-72. PubMed ID: 6794980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device.
    Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T
    Contraception; 1989 Feb; 39(2):195-204. PubMed ID: 2495893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first year of use.
    Ratsula K
    Contraception; 1987 Dec; 36(6):659-66. PubMed ID: 3128429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal changes during the first year of use of subdermal levonoregestrel implants, Norplant.
    Shaaban MM; el-Nashar IM; Ghaneimah SA; Gomaa AA; Salah M; Abdel-Aleem AM
    Contraception; 1984 Nov; 30(5):391-405. PubMed ID: 6440735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device.
    Nilsson CG; Lähteenmäki PL; Luukkainen T
    Fertil Steril; 1984 Jan; 41(1):52-5. PubMed ID: 6420203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal consequences of "missing the pill".
    Wang E; Shi S; Cekan SZ; Landgren BM; Diczfalusy E
    Contraception; 1982 Dec; 26(6):545-66. PubMed ID: 6820336
    [No Abstract]   [Full Text] [Related]  

  • 18. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate postabortal insertion of a levonorgestrel-releasing IUD.
    Heikkilä M; Lähteenmäki P; Luukkainen T
    Contraception; 1982 Sep; 26(3):245-59. PubMed ID: 6816506
    [No Abstract]   [Full Text] [Related]  

  • 20. The lack of interaction between temafloxacin and combined oral contraceptive steroids.
    Back DJ; Tjia J; Martin C; Millar E; Mant T; Morrison P; Orme M
    Contraception; 1991 Apr; 43(4):317-23. PubMed ID: 1906791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.